Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Allakos Inc.
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
February 26, 2024
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
February 12, 2024
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Announces a Restructuring to Focus on Development of AK006
January 16, 2024
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
January 16, 2024
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Appoints Neil Graham to its Board of Directors
August 30, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
August 09, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
August 02, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
June 12, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
June 05, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
November 29, 2022
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
November 10, 2022
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Allakos Inc.
Via
GlobeNewswire
Tickers
ALLK
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.